{"transactions":[{"id":843922,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":11250,"derivative":{"underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":843921,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1342,"price":55.225,"value":74111.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":7301,"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":843920,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":8643,"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":848690,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848689,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848688,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":2607,"price":60.108,"value":156701.556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":4893,"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848687,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":942141,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-09T18:52:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-009232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526009232/ownership.xml","form_type":"4"}},{"id":942140,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T18:52:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":80000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-009232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526009232/ownership.xml","form_type":"4"}},{"id":1207794,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-13T19:30:44.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-039020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000095017025039020/ownership.xml","form_type":"4"}},{"id":1207793,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-03-13T19:30:44.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":80000,"derivative":{"exercise_price":35.48,"expiration_date":"2035-03-11","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-039020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000095017025039020/ownership.xml","form_type":"4"}},{"id":1581136,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T18:34:36.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":100000,"derivative":{"exercise_price":44.37,"expiration_date":"2034-03-10","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-030228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000095017024030228/ownership.xml","form_type":"4"}},{"id":1954250,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T16:44:33.000Z","date":"2023-03-10","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":45000,"derivative":{"exercise_price":34.18,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-23-018501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000120919123018501/doc4.xml","form_type":"4"}},{"id":2121191,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-09T17:04:54.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on\nthe last day of each month."}],"balance_after":135000,"derivative":{"exercise_price":34.77,"expiration_date":"2032-11-06","underlying":"Common Shares","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-22-056248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000120919122056248/doc4.xml","form_type":"4"}},{"id":4005854,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":29797,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":29797},"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4005853,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":59595,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":59595},"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4005852,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":29797,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":29797},"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4005851,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":31818,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31818},"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4005850,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":7489,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7489},"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4005849,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-03-08T12:17:51.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":30600.2032,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 189.6457 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 8,584 shares subject to restricted stock units.  See also note 5."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the \"Merger Agreement\"), between the Company, Sanofi, a French soci?t? anonyme (the \"Parent\"), and Blink Acquisition Corp. (\"Merger Sub\"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $105.00 in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-18-010654","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218010654/form4.xml","form_type":"4"}},{"id":4034127,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-02-26T17:07:52.000Z","date":"2018-02-23","kind":"tax_withholding","acquired":false,"shares":917,"price":104.74,"value":96046.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":30410.5575,"source":{"system":"sec-edgar","filing":"0001127602-18-008437","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218008437/form4.xml","form_type":"4"}},{"id":4034126,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-02-26T17:07:52.000Z","date":"2018-02-22","kind":"tax_withholding","acquired":false,"shares":2011,"price":104.3,"value":209747.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":31327.5575,"source":{"system":"sec-edgar","filing":"0001127602-18-008437","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218008437/form4.xml","form_type":"4"}},{"id":4055155,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-15T16:59:38.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":3744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":7489,"derivative":{"underlying":"Common Stock","underlying_shares":3744},"source":{"system":"sec-edgar","filing":"0001127602-18-006414","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218006414/form4.xml","form_type":"4"}},{"id":4055154,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-02-15T16:59:38.000Z","date":"2018-02-14","kind":"tax_withholding","acquired":false,"shares":1136,"price":103.52,"value":117598.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":33338.5575,"source":{"system":"sec-edgar","filing":"0001127602-18-006414","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218006414/form4.xml","form_type":"4"}},{"id":4055153,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-02-15T16:59:38.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":3744,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34474.5575,"source":{"system":"sec-edgar","filing":"0001127602-18-006414","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218006414/form4.xml","form_type":"4"}},{"id":4079372,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-02T17:02:19.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":31818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."}],"balance_after":31818,"derivative":{"underlying":"Common Stock","underlying_shares":31818},"source":{"system":"sec-edgar","filing":"0001127602-18-003792","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760218003792/form4.xml","form_type":"4"}},{"id":4172872,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-11-03T16:06:47.000Z","date":"2017-11-02","kind":"tax_withholding","acquired":false,"shares":636,"price":53.65,"value":34121.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 548.5575 shares acquired under the Company's Employee Stock Purchase Plan on April 5, 2017, July 6, 2017 and September 29, 2017."}],"balance_after":30730.5575,"source":{"system":"sec-edgar","filing":"0001127602-17-031184","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217031184/form4.xml","form_type":"4"}},{"id":4371631,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T16:29:40.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":29797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":29797,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":29797},"source":{"system":"sec-edgar","filing":"0001127602-17-012951","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217012951/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4371630,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T16:29:40.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":59595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in full on the third anniversary of the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":59595,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":59595},"source":{"system":"sec-edgar","filing":"0001127602-17-012951","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217012951/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4371629,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T16:29:40.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":29797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":29797,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":29797},"source":{"system":"sec-edgar","filing":"0001127602-17-012951","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217012951/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4409940,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":718,"price":43.42,"value":31175.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":30818,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409939,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":918,"price":47.76,"value":43843.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":31536,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409938,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":285,"price":49.56,"value":14124.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":32454,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409937,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":532,"price":43.42,"value":23099.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":32739,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409936,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":1191,"price":47.76,"value":56882.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":33271,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409935,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":368,"price":49.56,"value":18238.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":34462,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409934,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":1155,"price":43.42,"value":50150.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":34830,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4409933,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:07:48.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":35019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes restricted stock units granted by Bioverativ Inc. (\"Bioverativ\") to the reporting person as a result of the conversion of existing Biogen Inc. (\"Biogen\") cash-settled performance units, market stock units and restricted stock units held by the reporting person prior to the spin-Off of Bioverativ from Biogen on February 1, 2017 (\"Spin-Off\"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 966 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off."}],"balance_after":35985,"source":{"system":"sec-edgar","filing":"0001127602-17-009670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217009670/form4.xml","form_type":"4"}},{"id":4442776,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T16:37:45.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":29744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in three equal annual installments beginning on February 14, 2018."}],"balance_after":29744,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":29744},"source":{"system":"sec-edgar","filing":"0001127602-17-006615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217006615/form4.xml","form_type":"4"}},{"id":4442775,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T16:37:45.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":59488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in full on the third anniversary of the date of grant."}],"balance_after":59488,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":59488},"source":{"system":"sec-edgar","filing":"0001127602-17-006615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217006615/form4.xml","form_type":"4"}},{"id":4442774,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T16:37:45.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":29744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in three equal annual installments beginning on February 14, 2018."}],"balance_after":29744,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":29744},"source":{"system":"sec-edgar","filing":"0001127602-17-006615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217006615/form4.xml","form_type":"4"}},{"id":4442773,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T16:37:45.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":11233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":11233,"derivative":{"underlying":"Common Stock","underlying_shares":11233},"source":{"system":"sec-edgar","filing":"0001127602-17-006615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000112760217006615/form4.xml","form_type":"4"}}]}